Author Guidelines

1. Journal Scope and General Information

Experimental Biomedical Research (EBR) publishes scientific articles in English in the field of experimental and biomedical research. The journal aims to publish scientifically sound, ethically conducted, clearly reported, and relevant research.

The journal does not provide translation services. Manuscripts whose English does not meet the minimum standard for scientific evaluation may be returned to authors or declined before peer review. Accepted manuscripts undergo copyediting for language and formal style.

Authors wishing to submit a Review Article should contact the Editor-in-Chief before submission.

2. Online Submission

Manuscripts must be submitted by the corresponding author through the journal’s online submission system. A complete submission should include the cover letter, author and co-author information, the main manuscript file, separate figure and supplementary files where applicable, conflict-of-interest disclosure, and ethics approval documentation where required.

If technical problems occur during submission, authors may contact the journal at info@experimentalbiomedicalresearch.com.

3. Submission Preparation Checklist

• The manuscript has not been previously published and is not under consideration by another journal, unless a clear explanation has been provided to the Editor.
• The submission file is provided in Microsoft Word or another format accepted by the online system.
• Reference information, including DOI or other persistent identifiers where available, has been checked for accuracy.
• The manuscript follows the journal’s formatting, stylistic, ethical, and bibliographic requirements.
• Tables and figures are appropriately cited and supplied in the format required by the journal.
• All authors have approved the manuscript and the submission.
• ORCID iDs and complete author information have been provided.
• Funding, conflicts of interest, ethics approval, informed consent, and other required declarations have been included.

4. Corresponding Author and Author Responsibilities

The corresponding author is responsible for completing the submission, maintaining the article and related documentation, providing original data or supporting information when reasonably requested, collecting author contribution and conflict-of-interest information, confirming that all authors approve the submission, and coordinating final proof approval.

Authorship should reflect substantial intellectual contribution to the work and responsibility for the published content. All authors should approve the final version and agree to be accountable for the integrity of the work.

Changes in authorship after submission should be requested with a clear explanation and confirmation from all affected authors. The journal may request supporting documentation.

5. ORCID iD

ORCID iDs of the corresponding author and all other authors should be provided during registration and submission. Authors without an ORCID iD are encouraged to register for one.

6. Author Declaration, Funding and Conflicts of Interest

The cover letter should confirm that the manuscript has not been published elsewhere and is not under consideration by another journal, and that all authors have approved the submission and, where applicable, the responsible institutional authorities have approved the work.

All authors must disclose commercial relationships, consulting activities, stock or share interests, patent or licensing arrangements, financial relationships, or other interests that could reasonably be perceived as conflicts. If no relevant conflicts exist, this should be stated explicitly. The corresponding author is responsible for ensuring that co-author disclosures are complete.

All sources of financial or material support should be disclosed, together with the role of the funder, where applicable, in study design, data collection, analysis, interpretation, writing, or the decision to submit. (Author Declaration Form & Conflict Of Interest Statement). 

7. Permissions and Copyrighted Material

Authors must obtain permission from the copyright holder for figures, tables, images, or substantial text previously published elsewhere when permission is required. Appropriate attribution must be provided. Authors are responsible for ensuring that all material submitted for publication may lawfully be reproduced.

8. Units, Abbreviations and Drug Names

Measurements should be reported using the International System of Units (SI). Abbreviations should be defined at first mention and then used consistently. Standard abbreviations and generic drug names should be used. If a registered trademark is necessary, the manufacturer’s name and country should be provided in parentheses after the generic name at first use.

9. Manuscript Preparation

9.1 Title Page

The title page should include the manuscript title, full names of all authors, institutional affiliations and addresses. Corresponding author information should include email address, 16-digit ORCID iD, telephone number(s), and full mailing address. Conflict-of-interest disclosures, funding information, and acknowledgments should be included in the designated final section of the title page where applicable.

9.2 Abstract

Abstracts must not exceed 250 words. For Original Research Articles, the abstract should use the headings Aim, Methods, Results, and Conclusions unless another structure is scientifically more appropriate. The abstract should not contain unexplained abbreviations or references and must accurately represent the manuscript.

9.3 Keywords

Provide 4–6 keywords. MeSH (Medical Subject Headings) terminology is recommended where appropriate.

9.4 Main Text

Original Research Articles should normally be organized under Introduction, Methods and Materials, Results, Discussion, and Conclusions. The manuscript should be prepared in Microsoft Word, using 12-point Times New Roman unless otherwise specified by the online submission system. References to literature, figures, and tables should appear in order of citation. Authors should avoid unnecessary formatting such as bold, italics, or underlining in the main text and should use generic drug names.

9.5 Introduction

The Introduction should provide the context and rationale for the study, identify the relevant problem or knowledge gap, and state the objective or hypothesis clearly and concisely.

9.6 Methods and Materials

The Methods and Materials section should describe the methods in sufficient detail to permit appropriate understanding and, where feasible, reproducibility. Sources of drugs and chemicals should be stated. Appropriate statistical methods should be described.

9.7 Results

The Results section should present findings derived from the methods described, in a clear and objective manner, with appropriate tables and figures where needed.

9.8 Discussion and Conclusions

The Discussion should interpret the findings in relation to the study objectives and relevant literature, address important inconsistencies or limitations, and avoid claims not supported by the data. Conclusions should be concise and supported by the results.

10. References

References should be numbered in the order in which they are first mentioned in the text and should not be alphabetized. In-text citations should use numbers in square brackets. References should follow AMA format and the NLM style, with journal names abbreviated according to Index Medicus.

For papers with 1–3 authors, all authors should be listed. For papers with more than 3 authors, list the first 3 authors followed by et al. Author names should be given as family name followed by initials without periods, separated by commas.

For online journals and articles published ahead of print, provide the DOI when available rather than the URL. URLs in references should not be converted into hyperlinks. Authors are responsible for the accuracy and completeness of references.

10.1 Reference Examples

Journal article: Dilek G, Calik Y, Ozkuk K. Effect of vitamin D level and polypharmacy on the risk of falls in the elderly. Exp Biomed Res. 2021;4(2):81-88.

More than three authors: Yenigun V, Azzawri A, Acar M, et al. Alcoholic extract of Tarantula cubensis (Theranekron®) induce autophagy on gastric cancer cells. Exp Biomed Res. 2021;4(2):89-98.

Book chapter: Luck H. Catalase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. New York: Academic Press; 1971. p. 885-893.

Online document: Provide author, title, site or publisher, citation date, and stable URL according to NLM style.

11. Figures, Tables and Supplementary Materials

Figures and tables should be numbered consecutively and cited in the text. Each table should have an explanatory heading and units should be included in column headings when numerical measurements are presented.

Figures should be supplied in appropriate vector or bitmap formats. Bitmap images should normally have a resolution of at least 300 dpi.

Authors may submit supplementary material such as audio files, video clips, or datasets. A section titled “Supplementary Material” should appear before the references and briefly describe each supplementary file. Authors are responsible for the accuracy and completeness of supplementary material.

12. English Language Editing

Manuscripts must meet an adequate standard of scientific English before peer review. Authors may seek assistance from a qualified colleague or a professional language-editing service. Use of a language-editing service does not imply or guarantee acceptance.

13. Ethical Standards and Research Integrity

EBR follows the principles and relevant guidance of the Committee on Publication Ethics (COPE) and the recommendations of the International Committee of Medical Journal Editors (ICMJE). Authors are expected to protect the integrity, credibility, and transparency of the scientific record.

The journal may screen submitted manuscripts using plagiarism-detection software, including iThenticate. Authors remain responsible for the originality and integrity of their work and must not engage in plagiarism, fabrication, falsification, inappropriate image manipulation, duplicate or redundant publication, or other forms of research and publication misconduct.

14. Artificial Intelligence (AI) in the Publication and Peer-Review Process

14.1 Use of AI by Authors

Authors may use artificial intelligence (AI) and AI-assisted technologies as supportive tools during manuscript preparation, including language refinement, grammar and spelling correction, translation, structural organization, improving clarity and readability, literature-related assistance, and other appropriate editorial or analytical support.

AI use must remain under meaningful human oversight. AI tools are assistive instruments and must not replace the authors’ scientific judgment, critical evaluation, interpretation, or academic responsibility. Authors remain fully responsible for the accuracy, originality, integrity, and ethical compliance of their work.

AI tools must not be used to fabricate or manipulate research data, results, references, images, or scientific conclusions. AI tools cannot be listed as authors or co-authors.

Authors should disclose substantive use of AI-assisted technologies at submission and in the manuscript where appropriate, including the name of the tool and the nature or purpose of its use. Where substantive AI-assisted technologies have been used, authors should disclose their use both in the cover letter and in the manuscript, as appropriate. The disclosure should be sufficiently clear to allow readers and editors to understand how AI contributed to the work. Routine spelling, grammar, punctuation, or basic language refinement does not require a separate disclosure. Authors must verify AI-assisted content, ensure appropriate attribution and citations, and remain responsible for avoiding plagiarism.

Authors should not enter confidential, unpublished, personal, or otherwise protected information into AI systems unless appropriate privacy and confidentiality safeguards are assured.

14.2 Use of AI by Reviewers

Reviewers may use AI and AI-assisted technologies only as supportive tools and in accordance with the journal’s policy. Such use must not compromise confidentiality, integrity, independence, or fairness.

Reviewers must not upload or disclose submitted manuscripts, unpublished data, figures, tables, supplementary material, or other confidential information to AI systems unless the journal has explicitly authorized such use and confidentiality can be assured.

AI may assist with appropriate non-decisional tasks, but the scientific assessment, interpretation, critical evaluation, and final recommendation remain under the reviewer’s human judgment and responsibility. Reviewers should disclose substantive use of AI to the journal.

14.3 AI and Authorship

AI tools cannot be authors or co-authors because they cannot assume responsibility or accountability for the accuracy, integrity, and originality of published work.

15. Research Involving Human Participants and/or Animals

Research involving human participants must comply with applicable ethical standards and must have approval from the appropriate institutional and/or national research ethics committee when required. The name of the committee and official approval/reference number should be stated in the Methods section.

Human participant research should state compliance with applicable ethical standards, including the Declaration of Helsinki where relevant.

Animal research should state compliance with applicable international, national, and/or institutional guidelines and approval by the appropriate animal care and research ethics committee. EBR supports the principles of Replacement, Reduction, and Refinement (3Rs).

Clinical trials should be prospectively registered in an appropriate public registry in accordance with applicable standards. The registration number should be reported in the manuscript.

15.1 Informed Consent and Privacy

Appropriate informed consent must be obtained from participants when required. Identifying information, including names, dates of birth, identification numbers, photographs, genetic profiles, or other distinguishing information, should not be published unless scientifically necessary and appropriate consent has been obtained.

For deceased participants, appropriate written permission from the family or estate should be obtained where required. If identifying characteristics are altered to protect anonymity, authors must ensure that the changes do not distort scientific meaning.

The journal may request documentation of consent. The journal reserves the right to reject manuscripts that do not comply with applicable ethical and consent requirements.

Authors may use this Patient Consent Form, which sent to the journal if requested.

16. Reporting Guidelines and Transparency

Authors are encouraged to use reporting guidelines appropriate to their study design, such as CONSORT for randomized trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic accuracy studies, and other relevant EQUATOR Network guidelines.

Authors should retain access to data and supporting materials necessary to verify the reported work and should provide appropriate information to the journal when reasonably requested.

17. Publication Charges

There are no submission fees, editorial processing charges, article processing charges (APCs), page charges, colour charges, or publication fees for Experimental Biomedical Research.

18. Copyright and License Policy

Copyright is retained by the author(s). Articles are published under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. Authors retain copyright and publishing rights and permit others to use, copy, redistribute, and adapt the work, provided appropriate credit is given to the authors and the original source.

19. Peer Review Policy and Process

19.1 Initial Editorial Assessment

All submissions undergo an initial editorial evaluation for relevance to the journal’s Aims & Scope, scientific originality and significance, methodological soundness, ethical compliance, formatting, and adherence to submission requirements. Manuscripts may be rejected at this stage without external review if they are outside the scope or do not meet minimum scientific or editorial standards. Language quality and plagiarism may also be assessed at this stage.

19.2 Double-Blind Peer Review

Experimental Biomedical Research follows a double-blind peer-review process. Each manuscript is normally evaluated by at least two independent expert reviewers using the EBR Electronic Reviewer Assessment Form.

Reviewers assess scientific rigor and experimental design; adequacy and reliability of data; validity of results and conclusions; methodological and statistical appropriateness; originality and scientific contribution; relevance to the journal’s readership; and clarity and organization.

19.3 Reviewer Recommendations

• Accept
• Minor Revision
• Major Revision
• Reject (resubmission allowed)
• Reject (no resubmission)

If significant discrepancies arise between reviewers, an additional reviewer may be consulted. Revised manuscripts are normally returned to the original reviewers together with the authors’ detailed responses.

19.4 Reviewer Responsibilities

Reviewers must maintain confidentiality, provide constructive and objective comments, respond within the agreed time, and disclose conflicts of interest. Reviewers must not appropriate authors’ ideas or use confidential manuscript information for personal purposes. Any assistance from another person should comply with journal policy and confidentiality requirements.

19.5 Editorial Decision

The final decision regarding acceptance or rejection rests with the Editor-in-Chief. Editorial decisions are based on reviewer evaluations, scientific merit, ethical compliance, and journal priorities. Editors do not participate in decisions involving manuscripts in which they have a conflict of interest; such manuscripts are handled independently.

The journal follows relevant COPE principles and relevant ICMJE recommendations.

20. Copyediting, Proofs and Publication

Accepted manuscripts undergo copyediting for language, formatting, and reference consistency. Authors must approve the final proof before publication.

Accepted articles are sent as PDF proofs by email to the relevant author. Proof corrections should be limited to typographical, factual, or formatting errors; substantial additions or deletions should not be introduced at proof stage. Authors should thoroughly check the proof and return corrections within 3 days.

Following final approval, the manuscript is prepared for online publication and assigned to an issue of the journal.

21. Post-Publication Correction and Retraction

A published article may require a Correction notice or Retraction. Such decisions are made after careful editorial assessment in accordance with relevant COPE guidance and are permanently linked to the original article to preserve the integrity and transparency of the scientific record.

21.1 Correction

An error or omission that may affect the interpretation of an article but does not impair its scientific integrity may be addressed through a Correction notice. Major errors will be accompanied by a notice describing the error and the changes made. Minor errors may be corrected in the article with an explanatory footnote rather than a separate notice, where appropriate.

21.2 Retraction

A Retraction may be issued for a major error in the analysis or methods that invalidates the results, or for serious research or publication misconduct, including research conducted without required ethical approval, fabricated data, manipulated images, plagiarism, or duplicate publication.

Retraction decisions are made in accordance with COPE principles in collaboration with the Editor-in-Chief and Editorial Team. A ‘Retracted’ watermark will be added to the published version where applicable. A separate retraction notice will be linked to the article, and the withdrawal statement will be paginated and published in the online issue.

22. Archiving and Repository Policy

EBR utilizes LOCKSS and CLOCKSS systems to support distributed digital preservation. Published articles are openly accessible with no embargo under the CC BY license. Authors retain copyright and publishing rights in accordance with the journal’s licensing policy.

23. Appeals and Complaints

Authors who believe that an editorial decision resulted from a significant procedural or factual error may submit a reasoned appeal to the editorial office. Appeals should address specific concerns and should not simply restate disagreement with scientific judgment.

Complaints concerning editorial processes, publication ethics, conflicts of interest, or other journal procedures will be assessed by the appropriate editorial authority in accordance with journal policy and relevant publication-ethics principles.

24. Editorial Independence, Privacy and Ethical Framework

EBR is committed to editorial independence, confidentiality, fairness, transparency, and research integrity. The journal’s editorial decisions are based on scientific and ethical considerations and are not influenced by commercial interests.

The journal follows relevant COPE principles and relevant ICMJE recommendations and may update its policies as international standards evolve.

Names and email addresses entered into the journal website are used exclusively for the stated purposes of the journal and are not made available for other purposes or to other parties.

Suggested AI Disclosure Statement

“During the preparation of this manuscript, the authors used [NAME OF AI TOOL] for [PURPOSE]. The authors reviewed and edited the content and take full responsibility for the accuracy, integrity, and final content of the manuscript.”

Key Editorial References

International Committee of Medical Journal Editors (ICMJE). Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Relevant recommendations, updated January 2026.

Committee on Publication Ethics (COPE). Core Practices and relevant publication-ethics guidance.

25. Website and Policy Consistency

The information published on the journal website, including the journal scope, editorial structure, peer-review process, submission requirements, publication model, fees, ethical policies, and contact information, should be accurate and kept up to date. The Author Guidelines provide the detailed requirements for authors; summary statements on other journal pages should remain consistent with these policies.

The journal may revise its policies when necessary to reflect changes in scholarly publishing standards, ethical guidance, or journal practice. Substantive policy changes will be communicated through the journal website as appropriate.

Author Forms and Resources

The following journal forms and resources are available to authors:

• Journal submission page
• ORCID
• Author Form / Resource 1
• MeSH
• NLM Reference Style / Uniform Requirements
• COPE
• ICMJE – Protection of Research Participants
• NC3Rs – The 3Rs
• Author Form / Resource 2
• ICMJE Recommendations
• Author Form / Resource 3
• Creative Commons CC BY 4.0
• COPE – Post-publication Discussions and Corrections